American Association for Cancer Research
15417786mcr190805-sup-226880_2_supp_5952564_q2blqh.xlsx (17.63 kB)

Supplementary Table S1 from AGO2 Mediates MYC mRNA Stability in Hepatocellular Carcinoma

Download (17.63 kB)
posted on 2023-04-03, 17:01 authored by Kai Zhang, Yotsawat Pomyen, Anna E. Barry, Sean P. Martin, Subreen Khatib, Lucy Knight, Marshonna Forgues, Dana A. Dominguez, Ravinder Parhar, Ashesh P. Shah, Adam S. Bodzin, Xin Wei Wang, Hien Dang

Supplemental Table S1. Correlation between differentially expressed miRNAs (DEmiRNAs) and differentially expressed mRNAs (DEmRNAs) in the TCGA dataset.


Intramural Research Program of the Center for Cancer Research



Deregulated RNA-binding proteins (RBP), such as Argonaute 2 (AGO2), mediate tumor-promoting transcriptomic changes during carcinogenesis, including hepatocellular carcinoma (HCC). While AGO2 is well characterized as a member of the RNA-induced silencing complex (RISC), which represses gene expression through miRNAs, its role as a bona fide RBP remains unclear. In this study, we investigated AGO2′s role as an RBP that regulates the MYC transcript to promote HCC. Using mRNA and miRNA arrays from patients with HCC, we demonstrate that HCCs with elevated AGO2 levels are more likely to have the mRNA transcriptome deregulated and are associated with poor survival. Moreover, AGO2 overexpression stabilizes the MYC transcript independent of miRNAs. These observations provide a novel mechanism of gene regulation by AGO2 and provide further insights into the potential functions of AGO2 as an RBP in addition to RISC. Authors demonstrate that the RBP Argonaute 2 stabilizes the MYC transcript to promote HCC.